| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 01/11/2001 | CA2375157A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | CA2373883A1 Method of reducing neuronal injury or apoptosis |
| 01/10/2001 | EP1066830A2 Uses and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 01/10/2001 | EP1066290A1 PYRROLO[1,2-a]PYRAZINE sPLA 2 INHIBITOR |
| 01/10/2001 | EP1066283A2 Substituted indolealkanoic acids |
| 01/10/2001 | EP1066273A1 Metalloproteinase inhibitors |
| 01/10/2001 | EP1066257A2 Heterocylic classes of compounds for the modulating tyrosine protein kinase |
| 01/10/2001 | CN1279670A Substituted oximes as neurokinin antagonists |
| 01/10/2001 | CN1279669A Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 01/10/2001 | CN1279612A Modulation of immune responses |
| 01/10/2001 | CN1279236A Salt as thrombin inhibitor |
| 01/10/2001 | CN1279106A Detoxicating, Stasis-dispersing, inflammation-relieving, antalgic and refreshing medicine and its preparing process |
| 01/10/2001 | CN1060378C Drop for otitis media |
| 01/10/2001 | CN1060351C Nutritive preparation for computer operator and its production technology |
| 01/09/2001 | US6172250 Hydrolysis of an organosilicon compounds |
| 01/09/2001 | US6172109 Side effect reduction; administering topically |
| 01/09/2001 | US6172068 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 01/09/2001 | US6172060 Therapy for sexual disorders |
| 01/09/2001 | US6171840 LacC from streptococcus pneumoniae |
| 01/09/2001 | US6171835 ribH |
| 01/09/2001 | US6171788 Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders |
| 01/09/2001 | US6171618 Combination dosage form comprising cetirizine and pseudoephedrine |
| 01/09/2001 | US6171603 Treating skin, hair, cardiovascular, autoimmune and vision disorders; administering as anticarcinogenic, antidepressant,antiinflammatory, and antiacne agents |
| 01/09/2001 | US6171598 GTP cyclohydrolase II (RIBA) |
| 01/09/2001 | US6171588 Anti-αvβ3 integrin antibody antagonists |
| 01/04/2001 | WO2001000859A1 Method of inducing angiogenesis by micro-organs |
| 01/04/2001 | WO2001000655A2 Therapeutic peptides derived from subsequences of bpi |
| 01/04/2001 | WO2001000618A1 Benzamide derivatives |
| 01/04/2001 | WO2001000587A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 01/04/2001 | WO2001000586A1 Compounds as selective agonists at alpha 2b or 2b/2c adrenergic receptors |
| 01/04/2001 | WO2001000247A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | WO2001000226A1 Ophthalmic ointments for treating infective eye diseases |
| 01/04/2001 | WO2001000210A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | WO2000062769A3 Use of ap-1 activators to treat glaucoma and ocular hypertension |
| 01/04/2001 | WO2000056358A3 Vaccine against streptococcus pneumoniae capsular polysaccharides |
| 01/04/2001 | WO2000053236A3 Methods and compositions for targeted drug delivery |
| 01/04/2001 | WO2000044761A3 Ketolide antibiotics |
| 01/04/2001 | CA2435411A1 Method of inducing angiogenesis by micro-organs |
| 01/04/2001 | CA2377541A1 Method of inducing angiogenesis by micro-organs |
| 01/04/2001 | CA2376859A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | CA2375952A1 Reverse-turn mimetics and methods relating thereto |
| 01/03/2001 | EP1065207A1 Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| 01/03/2001 | EP1064965A2 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 01/03/2001 | EP1064964A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064949A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064376A2 GFR$g(a)3 AND ITS USES |
| 01/03/2001 | EP1064256A1 Bicyclo [2.2.1] heptanes and related compounds |
| 01/03/2001 | EP1064254A2 Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents |
| 01/03/2001 | EP1064018A2 The use of isolated domains of type iv collagen to modify cell and tissue interactions |
| 01/03/2001 | EP1063996A1 Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin v receptors, even of v 1a? and v 2? receptors |
| 01/03/2001 | EP1063985A1 Benzoates derivatives for inhibiting angiogenesis |
| 01/03/2001 | EP1063885A1 Xylitol compositions for treating upper respiratory conditions |
| 01/03/2001 | EP0708776B1 Antiallergic imidazoazepines |
| 01/03/2001 | CN1278794A Substituted di-hydroxyl-indol derivatives as protein tyrosine kinase and as protein serine/threenine kinase inhibitors |
| 01/03/2001 | CN1278736A Hmanized antibodies to human gp39, compositions containing and therapeutic use thereof |
| 01/03/2001 | CN1278725A Indeno [1,2-c]-naphtho [1,2-C]- and benzo [6,7] cyclohepta [1,2-C] pyrazole derivatives |
| 01/03/2001 | CN1278724A Indeno [1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activty |
| 01/03/2001 | CN1060171C Substituted biphenyl isoxazole sulfonamides |
| 01/02/2001 | US6169090 Heterocyclic compounds and their therapeutic use |
| 01/02/2001 | US6169069 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating the eyes or eyelids |
| 01/02/2001 | US6168933 Nucleotide sequences coding a transport protein; for the classification, diagnosis, prevention, and treatment of defects in cell proliferation, lipid metabolism and transport |
| 01/02/2001 | US6168920 Extracellular adhesive proteins |
| 01/02/2001 | CA2183313C Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase |
| 01/01/2001 | WO2001003645A2 Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| 12/30/2000 | CA2313131A1 Compositions and treatment for diabetic complications |
| 12/30/2000 | CA2313105A1 Treatment for diabetic complications |
| 12/30/2000 | CA2313063A1 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 12/28/2000 | WO2000078953A2 Human transport proteins |
| 12/28/2000 | WO2000078952A2 Human rna metabolism proteins (rmep) |
| 12/28/2000 | WO2000078815A1 ANTI-αvβ3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE |
| 12/28/2000 | WO2000078746A1 Antiviral agents |
| 12/28/2000 | WO2000078731A1 5-cyano-2-aminopyrimidine derivatives |
| 12/28/2000 | WO2000078396A2 Topical ophthalmic mast cell stabilizers for treating allergic eye diseases |
| 12/28/2000 | WO2000078346A1 Novel anti-allergic agents |
| 12/28/2000 | WO2000078322A2 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| 12/28/2000 | WO2000078317A1 Integrin receptor antagonists |
| 12/28/2000 | WO2000078297A2 Stable xylometazoline and oxymetazoline solution |
| 12/28/2000 | WO2000044379B1 Methods for restoring and/or enhancing accommodation in pseudo phakia |
| 12/28/2000 | WO2000043495A3 33 human secreted proteins |
| 12/28/2000 | WO2000043373A3 Kinase inhibitors |
| 12/28/2000 | WO2000034474A3 Growth factor homolog zvegf3 |
| 12/28/2000 | CA2377524A1 Novel anti-allergic agents |
| 12/28/2000 | CA2376077A1 Integrin receptor antagonists |
| 12/28/2000 | CA2375493A1 Human transport proteins |
| 12/28/2000 | CA2375407A1 Rna metabolism proteins |
| 12/28/2000 | CA2375236A1 Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use |
| 12/28/2000 | CA2375211A1 Antiviral agents |
| 12/28/2000 | CA2375182A1 5-cyano-2-aminopyrimidine derivatives |
| 12/28/2000 | CA2374002A1 Topical ophthalmic mast cell stabilizers for treating allergic eye diseases |
| 12/28/2000 | CA2373375A1 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| 12/27/2000 | EP1063293A2 Transforming growth factor alpha H1 |
| 12/27/2000 | EP1063292A2 DNA encoding human alpha 1 adrenergic receptors and uses thereof |
| 12/27/2000 | EP1063291A2 DNA encoding human alpha 1 adrenergic receptors and uses thereof |
| 12/27/2000 | EP1062323A2 Methods of diagnosis and triage using cell activation measures |
| 12/27/2000 | EP1061943A1 Method of preventing the death of retinal neurons and treating ocular diseases |
| 12/27/2000 | EP1061913A2 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation |
| 12/27/2000 | EP1061912A1 Phenanthrofuran derivatives |
| 12/27/2000 | EP1061873A1 Use of corneal hardening agents in enzyme orthokeratology |
| 12/27/2000 | EP1061805A1 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 12/27/2000 | EP0821666B1 Derivatives of succinamide and their use as metalloproteinase inhibitors |